Related Experiment Videos
Rhabdomyolysis and statin therapy: relevance to the elderly
Domenic A Sica1, Todd W B Gehr
1Department of Medicine, Section of Clinical Pharmacology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298-0160, USA. dsica@hsc.vcu.edu
Insights
The risk of statin-induced rhabdomyolysis varies among drugs. Pravastatin and fluvastatin have lower risks, while drug interactions increase myotoxicity, especially in elderly patients on multiple medications.
Area of Science:
- Pharmacology
- Clinical Therapeutics
Background:
- The safety profile of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) is under scrutiny following cerivastatin withdrawal.
- Myotoxicity, including rhabdomyolysis, is a known class effect of statins, but risks vary among individual agents.
Purpose of the Study:
- To evaluate the differential risk of myotoxicity among various statins.
- To explore the role of drug metabolism and drug-drug interactions in statin-induced myotoxicity.
- To inform clinical decision-making regarding statin selection, particularly in vulnerable populations.
Main Methods:
- Review of existing literature on statin-associated myotoxicity.
- Analysis of pharmacokinetic properties, including cytochrome P-450 (CYP) 3A4 metabolism.
- Examination of the impact of drug-drug interactions on statin plasma concentrations and toxicity.
Main Results:
- Pravastatin and fluvastatin exhibit a lower propensity for muscle damage, partly due to their non-reliance on CYP3A4 metabolism.
- Drug-drug interactions are a primary driver of statin-induced myotoxicity, leading to elevated drug levels.
- Elderly patients, often on polypharmacy, face increased myotoxicity risk due to altered metabolism and drug interactions.
Conclusions:
- Statin-induced myotoxicity risk is not uniform across the class; some agents are safer.
- Careful consideration of drug metabolism pathways and potential drug interactions is crucial for safe statin prescribing.
- Individualized statin selection is paramount, especially for elderly patients with complex medication regimens, to mitigate myotoxicity risks.
Abstract:
A recent debate has emerged as to the risk-benefit ratio of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins). This debate has centered on the withdrawal of the HMG-CoA reductase inhibitor cerivastatin (Baycol). Its withdrawal was prompted by an unacceptably high rate of rhabdomyolysis associated with its use. The development of rhabdomyolysis in cerivastatin-treated patients surprised few, since myotoxicity is a class effect with HMG-CoA reductase inhibitors. What has sprung from the cerivastatin experience, though, is the concept of "guilt by association"; thus, other members of this class are now viewed in a similarly negative light. Such misgivings are understandable, but to a degree may be ill-advised, since differences exist in the risk and therefore the rate of rhabdomyolysis occurrence among the various HMG-CoA reductase inhibitors. In this regard, pravastatin and fluvastatin are least likely to provoke muscle cell damage, which, at least in part, relates to their not being metabolized by the cytochrome P-450 (CYP) 3A4 pathway. When muscle damage does occur with HMG-CoA reductase inhibitors, it is commonly the result of drug-drug interactions rather than a specific adverse response to HMG-CoA reductase inhibitor monotherapy. Such drug-drug interactions inevitably result in higher plasma concentrations of an HMG-CoA reductase inhibitor and thereby an increased risk of myotoxicity. A growing consensus supports an expanded use of HMG-CoA reductase inhibitors in elderly patients. Polypharmacy and altered drug metabolism both put the elderly patient at increased risk of myotoxicity when drugs in the HMG-CoA reductase inhibitor class are administered. Physicians must take many factors into account when selecting a member of the HMG-CoA reductase inhibitor class, particularly as relates to their use in the multiply medicated elderly patient.